Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.
Therapeutics that use mRNA-;like some of the COVID-19 vaccines-;have enormous potential for the prevention and treatment of many diseases.
Using a self-built inverted microscope complete with laser optical tweezers to capture DNA, Yale Cancer Center and University of California Davis researchers for the first time created a visualization of the full-length human BRCA2 protein at the single molecule level.
A pharmacology researcher at New York Institute of Technology College of Osteopathic Medicine (NYITCOM) has co-authored a new study that makes a strong case for why a golden spice commonly found in curry could enhance ovarian cancer treatments.
Although genetic mutations in BRCA1 or BRCA2 are associated with a younger onset of breast and ovarian cancer, women with these genetic mutations continue to face a high risk of cancer incidence after age 50, even if they have not been previously diagnosed with cancer.
Despite the fact that we all start out as an egg cell in one of our mother's ovaries, these human reproductive organs are surprisingly under-studied. Scientists have been working on creating in vitro models of human ovaries so that we can learn more about them and develop treatments for ovarian conditions, but most existing models use a combination of human and mouse cells, which do not faithfully replicate human ovary functions and take a long time to grow in the lab.
Genetic counseling and genetic testing for mutations in certain genes such as BRCA1 and BRCA2 genes -; can help people understand their risk of certain types of cancer that can run in families, and improve outcomes through prevention, early detection, and targeted treatments.
In recent years, a mass spectrometry process that can detect the amounts of drugs in a biological sample, such as blood, has become a powerful diagnostic tool for helping medical professionals identify and monitor levels of therapeutic drugs in patients, which can cause unwanted or dangerous side effects.
Recent research revealed that CAR T-cell therapy, a particular type of cancer treatment in which the immune system’s T cells are directed to kill tumor cells, is successful in treating ovarian cancer in mice.
CAR T-cell therapy, a certain kind of cancer treatment in which the immune system's T cells are programmed to attack tumor cells, is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer.
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Certain prostate cancer patients have genetic mutations that could affect how they are treated. According to a study published in Urology Practice®, an Official Journal of the American Urological Association (AUA), a comprehensive, on-site genetic testing program developed by urologists could help close the gap for this underutilized resource.
Mutations in the BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 persons, respectively, elevate the risk of various malignancies such as ovarian, breast, pancreatic, and prostate cancer considerably.
With a $2.5 million fund received from the Medical Research Future Fund (MRFF), a new genomics project led by WEHI will develop precision medicine and customized cancer therapy for Australians.
Cancer spreads via circulating tumor cells (CTCs) that travel through the blood to other organs, and they are nearly impossible to track.
To drive anabolic processes, epithelial ovarian cancer (EOC) is heavily reliant on the tricarboxylic acid (TCA) cycle and oxidative phosphorylation.
Lung cancer affects approximately 48,500 persons in the United Kingdom every year. New treatments are urgently needed because only around 20% of patients live 5 years after diagnosis, and it is the leading cause of cancer death.
CAR T therapy, or chimeric antigen receptor T-cell therapy, has revolutionized the treatment of some blood cancers, allowing patients with relapsed or refractory disease to live longer and better lives.
Researchers are rushing to review a group of bacteria known as actinomycetes, which are one of the most successful sources of treatment.
Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer.
Ovarian cancer is a difficult to diagnose malignancy that is often caught at a more advanced stage. Treatments for this cancer have changed little over the past few decades, with surgery and chemotherapy being the most common therapeutic approaches.